Sudarshan Pharma Industries, a small-cap pharmaceutical company, experienced a 4% increase in its share price on May 4, 2026, following the announcement of strong Q4 financial results. The company reported a 44.8% rise in net profit for the quarter, amounting to ₹10.73 crore, compared to ₹7.41 crore in the same quarter last year. Revenue also saw a significant increase of 36.72%, reaching ₹220.92 crore from ₹161.59 crore year-on-year. For the full financial year, net profit surged 55.64% to ₹23.30 crore, while annual sales climbed 39.21% to ₹703.06 crore. These results indicate strong operational momentum, reflecting healthy growth metrics. Additionally, Sachin Mehta will resign as Chief Financial Officer effective May 1, 2026, while continuing as Joint Managing Director, ensuring a smooth transition. The stock has shown impressive performance, with a 310.05% return over the last two years and a 47.62% increase in the past three months, highlighting ongoing investor enthusiasm.